87333-19-5 Usage
Description
Ramipril, also known by the brand name Altace, is a prodrug that functions as an angiotensin-converting enzyme (ACE) inhibitor. It is metabolized in the liver to its active form, ramiprilat, which effectively inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Ramipril is a long-acting, tissue-specific, and non-sulfhydryl ACE inhibitor that is used for treating mild to moderate hypertension, congestive heart failure, and nephropathy. Additionally, it can prevent heart attacks, strokes, and cardiovascular death, and is also used to treat kidney damage due to diabetes with protein-containing urine.
Used in Pharmaceutical Industry:
Ramipril is used as an antihypertensive agent for the treatment of hypertension, as it helps lower blood pressure by inhibiting the production of angiotensin II.
Ramipril is used as a cardioprotective agent for the treatment of congestive heart failure and to prevent heart attacks, strokes, and cardiovascular death, due to its ability to reduce the harmful effects of angiotensin II on the heart.
Ramipril is used as a renoprotective agent for the treatment of nephropathy and prevention of renal complications in diabetes, as it helps protect the kidneys from damage caused by high blood pressure and diabetes.
Ramipril is used as an ACE inhibitor for the treatment of mild to moderate hypertension, as it blocks the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and lowering blood pressure.
References
https://en.wikipedia.org/wiki/Ramipril
https://www.drugbank.ca/drugs/DB00178
Clinical Use
Angiotensin-converting enzyme inhibitor:
Hypertension
Secondary prevention of myocardial infarction (MI),
stroke or cardiovascular death
Heart failure
Diabetic nephropathy
Veterinary Drugs and Treatments
Ramipril is a long-acting angiotensin converting enzyme (ACE) inhibitor
that may be useful in treating heart failure or hypertension
in dogs or cats. It is an approved product in the UK for treating
heart failure in dogs. In cats, ramipril has been used for treating
arterial hypertension. A recent study (MacDonald, Kittleson et al.
2006) did not show any significant benefit using ramipril in treating
Maine Coon cats with hypertrophic cardiomyopathy without
heart failure.
Like other ACE inhibitors, it may potentially be useful as adjunctive
treatment in chronic renal failure and protein losing nephropathies.
In dogs with moderate renal impairment (such as might be
found with CHF), there is apparently no need to adjust ramipril
dosage.
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: antagonism of hypotensive effect and
increased risk of renal impairment with NSAIDs;
hyperkalaemia with ketorolac and other NSAIDs.
Antihypertensives: increased risk of hyperkalaemia,
hypotension and renal failure with ARB’S and aliskiren.
Bee venom extract: possible severe anaphylactoid
reactions when used together.
Ciclosporin: increased risk of hyperkalaemia and
nephrotoxicity.
Cytotoxics: increased risk of angioedema with
everolimus.
Diuretics: enhanced hypotensive effect;
hyperkalaemia with potassium-sparing diuretics.
ESAs: increased risk of hyperkalaemia; antagonism
of hypotensive effect.
Gold: flushing and hypotension with sodium
aurothiomalate.
Lithium: reduced excretion (possibility of enhanced
lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia and
nephrotoxicity
Metabolism
Ramipril is metabolised in the liver to its active
metabolite, ramiprilat, and other inactive metabolites.
It is excreted mainly in the urine, as ramiprilat, other
metabolites, and some unchanged drug. About 40% of an
oral dose appears in the faeces; this may represent both
biliary excretion and unabsorbed drug.
Check Digit Verification of cas no
The CAS Registry Mumber 87333-19-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,3,3 and 3 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 87333-19:
(7*8)+(6*7)+(5*3)+(4*3)+(3*3)+(2*1)+(1*9)=145
145 % 10 = 5
So 87333-19-5 is a valid CAS Registry Number.
InChI:InChI=1/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
87333-19-5Relevant articles and documents
Drug intermediate in ACE- inhibitor synthesis and application thereof
-
Paragraph 0014, (2020/03/17)
Compound (I) of Formula, wherein R1 is aryl or alkyl ;R2 represents alkyl ;R3 represents alkyl or aralkyl, is a valuable pharmacological intermediate, which may be prepared by reacting a compound of Formula (IV) above (with thionyl chloride as defined above R1 in particular by reacting a compound of Formula R2 with thionyl chloride), especially for use in the preparation, inhibitor, such as for example for (VI) eperindopril or ramipril 2. ((I). The compound X of Formula . R3 is as defined (I) above). wherein (II) and (are defined above ACE. R1 and R2 wherein R is. a compound, of formula,).
PROCESS FOR THE PREPARATION OF RAMIPRIL
-
Page/Page column 52, (2016/01/01)
An enantioselective process for the production of (2S,3aS,6aS)-cyclopenta[b]pyrrole-2-carboxylic acid and its conversion into Ramipril is provided.
PROCESS FOR THE PREPARATION OF AMIDES OF N-[1-(S)-(ETHOXYCARBONYL)-3-PHENYLPROPYL]-L-ALANINE
-
Page/Page column 20, (2015/01/07)
A process for the production of amides of N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine is described. The process can be used for the production of key intermediates and finally the ACE inhibitors such as Ramipril, Enalapril, Quinapril, Trandolapril, Delapril and Moexipril starting from N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine by the reaction with the appropriate amines.
